PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease Reportsfollicular lymphoma
MeSH D008224 - follicular lymphoma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D008228:Non-hodgkin lymphoma
58 Companies
24 Drugs
$
Success rate
D008224: 
Follicular lymphoma
11 Companies
10 Drugs
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Acrotech BiopharmaIbritumomab tiuxetan Zevalin  2002-02-19   
BayerCopanlisib Aliqopa 2024-05-13 2017-09-14   
Bristol Myers SquibbLisocabtagene maraleucel Breyanzi  2022-04-04 $585 M Q4/23-Q3/24 
Ceft BioPharmaIbritumomab tiuxetan Zevalin  2004-01-16   
GenentechObinutuzumab Gazyva  2013-11-01   
Mosunetuzumab Lunsumio  2022-12-22   
Gilead SciencesAxicabtagene ciloleucel Yescarta  2018-08-23 $1,549 M Q4/23-Q3/24 
KrkaLenalidomide Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto)  2021-02-11   
Lenalidomide Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka)  2021-02-11   
Lenalidomide Lenalidomide Krka d.d  2021-02-11   
Merck & CoInterferon alfa-2b IntronA  2000-03-09   
RocheObinutuzumab Gazyvaro  2014-07-22   
Mosunetuzumab Lunsumio  2022-06-03   
Secura BioDuvelisib Copiktra  2021-05-19   
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
78%
108/139
Phase 2
27%
37/138
Phase 3
48%
28/58
Approved: 12Overall Success rate: 10%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Bayer
Copanlisib,
Tbo-filgrastim,
Lenograstim,
Calcium dobesilate,
Arm1,
Arm2
Bristol Myers Squibb
Lisocabtagene maraleucel,
ULOCUPLUMAB,
Ibi301,
Arm1,
Arm2,
Cc5013,
Cmab819,
Evidence,
Tqb2303
Genentech
Obinutuzumab,
Mosunetuzumab,
Ademetionine,
Calcium dobesilate,
Doconexent,
Terfenadine,
Imgatuzumab,
Sodium lactate,
Bevifimod,
Muromonab-cd3,
PINATUZUMAB VEDOTIN,
Microcrystalline cellulose,
Caelyx,
Doxorubin,
Hydroxydaunomycin,
Cc5013,
Evidence,
Abt199,
Sominex
Gilead Sciences
Axicabtagene ciloleucel,
Benzocaine,
Entospletinib,
Epratuzumab,
Ademetionine,
Doconexent,
LANRAPLENIB,
Imgatuzumab,
Veltuzumab,
Caelyx,
Doxorubin,
Hydroxydaunomycin,
Cc5013
Merck & Co
Interferon alfa-2b,
Ademetionine,
Regramostim,
Zilovertamab,
Imgatuzumab,
Albinterferon alfa-2b,
Bevifimod,
Zoptarelin doxorubicin,
Cirmtuzumab,
Anthracycline,
Caelyx,
Doxorubin,
Ibi301,
Mk3475,
Sagramostim,
Solumedrol,
Arm1,
Flt3l,
Hydroxydaunomycin,
Cc5013,
Tqb2303
Roche
Obinutuzumab,
Mosunetuzumab,
Tbo-filgrastim,
Tiragolumab,
Enoblituzumab,
Rimiducid,
Idasanutlin,
Lenograstim,
Ademetionine,
Doconexent,
Sodium lactate,
Aspartame,
Bevifimod,
Microcrystalline cellulose,
Corticoids,
Caelyx,
Doxorubin,
Vp16,
Solumedrol,
Arm1,
For46,
Hydroxydaunomycin,
Arm2,
Cc5013,
Abt199
Secura Bio
Duvelisib
TG Therapeutics
Umbralisib
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use